IL183285D0 - Glp-1 analog fusion protein formulations - Google Patents

Glp-1 analog fusion protein formulations

Info

Publication number
IL183285D0
IL183285D0 IL18328507A IL18328507A IL183285D0 IL 183285 D0 IL183285 D0 IL 183285D0 IL 18328507 A IL18328507 A IL 18328507A IL 18328507 A IL18328507 A IL 18328507A IL 183285 D0 IL183285 D0 IL 183285D0
Authority
IL
Israel
Prior art keywords
glp
fusion protein
protein formulations
analog fusion
analog
Prior art date
Application number
IL18328507A
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US64169004P priority Critical
Priority to PCT/US2005/045376 priority patent/WO2006068910A1/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL183285D0 publication Critical patent/IL183285D0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
IL18328507A 2004-12-22 2007-05-17 Glp-1 analog fusion protein formulations IL183285D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US64169004P true 2004-12-22 2004-12-22
PCT/US2005/045376 WO2006068910A1 (en) 2004-12-22 2005-12-15 Glp-1 analog fusion protein formulations

Publications (1)

Publication Number Publication Date
IL183285D0 true IL183285D0 (en) 2007-09-20

Family

ID=36123207

Family Applications (1)

Application Number Title Priority Date Filing Date
IL18328507A IL183285D0 (en) 2004-12-22 2007-05-17 Glp-1 analog fusion protein formulations

Country Status (22)

Country Link
US (1) US20090232807A1 (en)
EP (2) EP2168982A1 (en)
JP (1) JP2008525452A (en)
KR (1) KR100879662B1 (en)
CN (1) CN101044162B (en)
AT (1) AT435235T (en)
AU (1) AU2005319432A1 (en)
BR (1) BRPI0519393A2 (en)
CA (1) CA2589647A1 (en)
CY (1) CY1109269T1 (en)
DE (1) DE602005015257D1 (en)
DK (1) DK1831252T3 (en)
EA (1) EA011166B1 (en)
ES (1) ES2326906T3 (en)
HK (1) HK1107570A1 (en)
IL (1) IL183285D0 (en)
MX (1) MX2007007565A (en)
NO (1) NO20073372L (en)
PT (1) PT1831252E (en)
SI (1) SI1831252T1 (en)
UA (1) UA87009C2 (en)
WO (1) WO2006068910A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100888022B1 (en) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 Fusion Proteion of Imunoglobulin Fc and Human Apolipoproteina Kringle Fragment
JP2008169195A (en) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd Insulinotopic peptide drug combo using carrier material
CN101730523A (en) * 2007-07-10 2010-06-09 伊莱利利公司 Glp-1-fc fusion protein formulation
EP2031064A1 (en) * 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Method for increasing protein titres
US20120231022A1 (en) 2009-05-28 2012-09-13 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonist compounds for sleep enhancement
EP2496249B1 (en) 2009-11-03 2016-03-09 Amylin Pharmaceuticals, LLC Glp-1 receptor agonist for use in treating obstructive sleep apnea
AU2010353685B2 (en) * 2010-05-17 2014-09-25 Betta Pharmaceuticals Co., Ltd. Novel glucagon like peptide analogs, composition, and method of use
CN102533655A (en) * 2010-12-21 2012-07-04 青岛黄海制药有限责任公司 CHO-S cell strain for efficient expression type human recombinant protein GLP1/Fc and establishment method thereof
US9161953B2 (en) 2010-12-22 2015-10-20 Amylin Pharmaceuticals, Llc GLP-1 receptor agonists for islet cell transplantation
AR094821A1 (en) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd liquid formulation of an insulinotropic peptide conjugate prolonged action
MX2015008077A (en) 2012-12-21 2015-10-30 Sanofi Sa Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists.
CN104173275A (en) * 2013-05-21 2014-12-03 深圳翰宇药业股份有限公司 Dulaglutide injection and preparation method thereof
CN104371019A (en) 2013-08-13 2015-02-25 杭州鸿运华宁生物医药工程有限公司 Antibody capable of being specifically combined with GLP-1R and fusion protein of antibody and GLP-1
TW201609796A (en) 2013-12-13 2016-03-16 Sanofi Sa Non-acylated EXENDIN-4 peptide analogues
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201625669A (en) 2014-04-07 2016-07-16 Sanofi Sa Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
TW201625668A (en) 2014-04-07 2016-07-16 Sanofi Sa Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
TW201625670A (en) 2014-04-07 2016-07-16 Sanofi Sa Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN104327187B (en) * 2014-10-11 2018-06-08 上海兴迪金生物技术有限公司 Recombinant human GLP-1-Fc fusion protein
WO2016077806A1 (en) * 2014-11-13 2016-05-19 AskGene Pharma, Inc. Fusion proteins with dual receptor agonist activities
WO2016127887A1 (en) * 2015-02-11 2016-08-18 杭州鸿运华宁生物医药工程有限公司 Stabilized solution preparation of pharmaceutical glp-1r antibody fusion protein
AR105284A1 (en) 2015-07-10 2017-09-20 Sanofi Sa Exendin-4 derivatives as dual specific peptide agonists receptor glp-1 / glucagon
MX2018007859A (en) 2015-12-23 2018-11-09 Amgen Inc Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists.
GB201621987D0 (en) * 2016-12-22 2017-02-08 Archer Virgil L See Archer Sheri A Arecor Ltd Novel composition
WO2018237097A1 (en) 2017-06-20 2018-12-27 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118666A (en) * 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
WO1996004388A1 (en) * 1994-07-29 1996-02-15 Smithkline Beecham Plc Novel compounds
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
US6376653B1 (en) * 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies
IL155812D0 (en) * 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US20030191056A1 (en) * 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
WO2005000892A2 (en) * 2003-06-12 2005-01-06 Eli Lilly And Company Glp-1 analog fusion plroteins

Also Published As

Publication number Publication date
NO20073372L (en) 2007-07-16
EA200701364A1 (en) 2007-10-26
CA2589647A1 (en) 2006-06-29
HK1107570A1 (en) 2011-07-22
AU2005319432A1 (en) 2006-06-29
EP1831252A1 (en) 2007-09-12
AT435235T (en) 2009-07-15
JP2008525452A (en) 2008-07-17
WO2006068910A1 (en) 2006-06-29
CN101044162A (en) 2007-09-26
SI1831252T1 (en) 2009-12-31
PT1831252E (en) 2009-09-17
BRPI0519393A2 (en) 2009-01-20
CN101044162B (en) 2010-10-27
DE602005015257D1 (en) 2009-08-13
UA87009C2 (en) 2009-06-10
EA011166B1 (en) 2009-02-27
ES2326906T3 (en) 2009-10-21
CY1109269T1 (en) 2014-07-02
DK1831252T3 (en) 2009-10-05
EP1831252B1 (en) 2009-07-01
US20090232807A1 (en) 2009-09-17
EP2168982A1 (en) 2010-03-31
KR100879662B1 (en) 2009-01-20
MX2007007565A (en) 2007-07-24
KR20070089187A (en) 2007-08-30

Similar Documents

Publication Publication Date Title
IL176894A (en) Albumin fusion proteins comprising two or more tandemly oriented glp-1 polypeptides
EP1730148A4 (en) Aminobenzoxazoles as therapeutic agents
IL162642D0 (en) Formulations
GB0505250D0 (en) Hydrogel formulations
EP1534730A4 (en) Modified transferin-antibody fusion proteins
EP1594530A4 (en) Albumin fusion proteins
HK1069296A1 (en) Chair
ZA200703445B (en) Nanoparticulated whey proteins
EP1836314A4 (en) Modified human growth hormone
EP1750754A4 (en) Human glp-1 mimetibodies, compositions, methods and uses
PL1765292T3 (en) Abuse-deterrent drug formulations
IL181697D0 (en) Medicinal composition
EP1906795A4 (en) Canopy chair
IL184341D0 (en) Stabilized liquid polypeptide formulations
EP1824796A4 (en) Protein scaffolds and uses thereof
GB0404574D0 (en) Amino acids
IL188102D0 (en) Self-buffering protein formulations
EP1988922A4 (en) Protein formulations
GB0419408D0 (en) 741 chimeric polypeptides
EP1924596A4 (en) Albumin fusion proteins
IL211393D0 (en) Antibody formulations
IL178885D0 (en) Mutant pneumolysim proteins
GB0302671D0 (en) Pharmaceutical formulations
SI1641483T1 (en) Fusion proteins
SG10201606278UA (en) Peptide